Chemobrain: A critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy

Cytokine

Volumn 72, Issue 1, 2015, Pages 86-96

  Wang, Xiao Min ^a   Walitt, Brian ^b   Saligan, Leorey ^b   Tiwari, Agnes F Y ^a   Cheung, Chi Wai ^a   Zhang, Zhang Jin ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer chemotherapy; Chemobrain; Cognition dysfunction; Cytokines and epigenetics

Indexed keywords

ANTIINFECTIVE AGENT; BETAINE; CREBINOSTAT; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; METHOTREXATE; PACLITAXEL; S ADENOSYLMETHIONINE; SIRTUIN; TAXANE DERIVATIVE; THALIDOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER PATIENT; CANCER SURVIVOR; CAUSAL ATTRIBUTION; CENTRAL NERVOUS SYSTEM; CHEMOBRAIN; COGNITION; COGNITIVE DEFECT; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; HUMAN; MEMORY DISORDER; METABOLISM; NONHUMAN; REVIEW; SYNAPTIC TRANSMISSION; SYNDROME; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; GENETIC EPIGENESIS; NEOPLASMS; PATHOPHYSIOLOGY; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; BRAIN; COGNITION DISORDERS; CYTOKINES; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 84922279139     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.12.006     Document Type: Review

References (133)

1. Berger A., Shuster J.L., Von Roenn J.H. Principles and practice of palliative care and supportive oncology. vol. xvii 2013, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. 4th ed.
2. Cull A., et al. What do cancer patients mean when they complain of concentration and memory problems?. Br J Cancer 1996, 74(10):1674-1679.
3. Ahles T.A., Root J.C., Ryan E.L. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 2012, 30(30):3675-3686.
4. Ahles T.A., et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008, 110(1):143-152.
5. Wefel J.S., et al. 'Chemobrain' in breast carcinoma?: A prologue. Cancer 2004, 101(3):466-475.
6. Wefel J.S., et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004, 100(11):2292-2299.
7. Wefel J.S., et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010, 116(14):3348-3356.
8. Silberfarb P.M. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med 1983, 34:35-46.
9. de Ruiter M.B., et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2011, 32(8):1206-1219.
10. Heflin L.H., et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 2005, 97(11):854-856.
11. Vardy J., et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008, 19(4):623-629.
12. Debess J., et al. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 2010, 121(1):91-100.
13. Donovan K.A., et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2005, 104(11):2499-2507.
14. Galica J., et al. The impact of chemotherapy-induced cognitive impairment on the psychosocial adjustment of patients with nonmetastatic colorectal cancer. Clin J Oncol Nurs 2012, 16(2):163-169.
15. Hermelink K., et al. Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 2010, 19(12):1321-1328.
16. Kurita K., et al. Long-term cognitive impairment in older adult twins discordant for gynecologic cancer treatment. J Gerontol A Biol Sci Med Sci 2011, 66(12):1343-1349.
17. Tager F.A., et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 2010, 123(1):25-34.
18. Jansen C.E., et al. Chemotherapy-induced cognitive impairment in women with breast cancer: a critique of the literature. Oncol Nurs Forum 2005, 32(2):329-342.
19. Ahles T.A., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20(2):485-493.
20. van Dam F.S., et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998, 90(3):210-218.
21. Mehnert A., et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007, 66(1):108-118.
22. Poppelreuter M., et al. Cognitive dysfunction and subjective complaints of cancer patients. a cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004, 40(1):43-49.
23. Downie F.P., et al. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology 2006, 15(10):921-930.
24. Shilling V., et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational longitudinal study. Breast 2005, 14(2):142-150.
25. Reid-Arndt S.A., Hsieh C., Perry M.C. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology 2010, 19(5):535-544.
26. Fliessbach K., et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005, 64(7):1184-1188.
27. Weis J., Poppelreuter M., Bartsch H.H. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results. Psychooncology 2009, 18(7):775-782.
28. Poppelreuter M., Weis J., Bartsch H.H. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol 2009, 27(2):274-296.
29. Hutchinson A.D., et al. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 2012, 38(7):926-934.
30. Bruno J., Hosseini S.M., Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis 2012, 48(3):329-338.
31. Deprez S., et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 2011, 32(3):480-493.
32. Wefel J.S., et al. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011, 12(7):703-708.
33. Minton O., Stone P.C. A comparison of cognitive function, sleep and activity levels in disease-free breast cancer patients with or without cancer-related fatigue syndrome. BMJ Support Palliat Care 2013, 2(3):231-238.
34. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7(3):192-201.
35. McDonald B.C., et al. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol 2012, 30(20):2500-2508.
36. Inagaki M., et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007, 109(1):146-156.
37. Deprez S., et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012, 30(3):274-281.
38. de Ruiter M.B., et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp 2012, 33(12):2971-2983.
39. Button K.S., et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013, 14(5):365-376.
40. Walitt B., et al. Automated neuropsychiatric measurements of information processing in fibromyalgia. Rheumatol Int 2008, 28(6):561-566.
41. Glass J.M. Review of cognitive dysfunction in fibromyalgia: a convergence on working memory and attentional control impairments. Rheum Dis Clin North Am 2009, 35(2):299-311.
42. Ocon A.J. Caught in the thickness of brain fog: exploring the cognitive symptoms of chronic fatigue syndrome. Front Physiol 2013, 4:63.
43. Wolfe F., et al. The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010, 62(5):600-610.
44. Holmes G.P., et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988, 108(3):387-389.
45. Nebel M.B., Gracely R.H. Neuroimaging of fibromyalgia. Rheum Dis Clin North Am 2009, 35(2):313-327.
46. Williams D.A., Clauw D.J. Understanding fibromyalgia: lessons from the broader pain research community. J Pain 2009, 10(8):777-791.
47. Janelsins M.C., et al. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 2011, 38(3):431-438.
48. Wang X.M., et al. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012, 59(1):3-9.
49. Cleeland C.S., et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003, 97(11):2919-2925.
50. Mantovani A., Pierotti M.A. Cancer and inflammation: a complex relationship. Cancer Lett 2008, 267(2):180-181.
51. Lyon D., et al. Potential epigenetic mechanism(s) associated with the persistence of psychoneurological symptoms in women receiving chemotherapy for breast cancer: a hypothesis. Biol Res Nurs 2013.
52. Trask P.C., et al. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000, 18(11):2316-2326.
53. Glaser R., Kiecolt-Glaser J.K. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 2005, 5(3):243-251.
54. Gibb J., Al-Yawer F., Anisman H. Synergistic and antagonistic actions of acute or chronic social stressors and an endotoxin challenge vary over time following the challenge. Brain Behav Immun 2013, 28:149-158.
55. Capuron L., Ravaud A., Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2001, 63(3):376-386.
56. Tsavaris N., et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002, 87(1):21-27.
57. Pusztai L., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25(3):94-102.
58. Penson R.T., et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000, 10(1):33-41.
59. Janelsins M.C., et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer 2012, 20(4):831-839.
60. Villani F., et al. Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. Tumori 2008, 94(6):803-808.
61. Kesler S., et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun 2013, 30(Suppl):S109-S116.
62. Pomykala K.L., et al. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav 2013, 7(4):511-523.
63. Bower J.E., et al. Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol 2013, 31(13):1656-1661.
64. Tangpong J., et al. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 2006, 23(1):127-139.
65. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104(4):788-793.
66. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000, 157(5):683-694.
67. Wilson C.J., Finch C.E., Cohen H.J. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002, 50(12):2041-2056.
68. Kelley K.W. A new look for brain, behavior, and immunity. Brain Behav Immun 2003, 17(1):1-2.
69. Banks W.A., Erickson M.A. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 2010, 37(1):26-32.
70. Pan W., Kastin A.J. Interactions of cytokines with the blood-brain barrier: implications for feeding. Curr Pharm Des 2003, 9(10):827-831.
71. Felger J.C., Lotrich F.E. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246C:199-229.
72. Raison C.L., Miller A.H. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003, 54(3):283-294.
73. Bower J.E., et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002, 64(4):604-611.
74. Greenberg D.B., et al. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 1993, 8(4):196-200.
75. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27(1):24-31.
76. Chen Y., et al. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007, 7(3):147-156.
77. Tangpong J., et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem 2007, 100(1):191-201.
78. Aluise C.D., et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med 2011, 50(11):1630-1638.
79. Caldecott K.W. DNA single-strand breaks and neurodegeneration. DNA Repair (Amst) 2004, 3(8-9):875-882.
80. Abner C.W., McKinnon P.J. The DNA double-strand break response in the nervous system. DNA Repair (Amst) 2004, 3(8-9):1141-1147.
81. Blasiak J., et al. DNA damage and repair in type 2 diabetes mellitus. Mutat Res 2004, 554(1-2):297-304.
82. Nadin S.B., et al. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. Cancer Lett 2006, 239(1):84-97.
83. Aluise C.D., et al. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 2010, 678:147-156.
84. Stenvinkel P., et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease?. J Intern Med 2007, 261(5):488-499.
85. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33(Suppl):245-254.
86. Heim C., Binder E.B. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Exp Neurol 2012, 233(1):102-111.
87. Maze I., Nestler E.J. The epigenetic landscape of addiction. Ann N Y Acad Sci 2011, 1216:99-113.
88. Mifsud K.R., et al. Epigenetic mechanisms in stress and adaptation. Brain Behav Immun 2011, 25(7):1305-1315.
89. Adwan L., Zawia N.H. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol Ther 2013, 139(1):41-50.
90. Levenson J.M., et al. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem 2006, 281(23):15763-15773.
91. Miller C.A., Campbell S.L., Sweatt J.D. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Neurobiol Learn Mem 2008, 89(4):599-603.
92. Molfese D.L. Advancing neuroscience through epigenetics: molecular mechanisms of learning and memory. Dev Neuropsychol 2011, 36(7):810-827.
93. Sultan F.A., Day J.J. Epigenetic mechanisms in memory and synaptic function. Epigenomics 2011, 3(2):157-181.
94. Bilinski P., et al. Epigenetic regulation in drug addiction. Ann Agric Environ Med 2012, 19(3):491-496.
95. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159.
96. Briones T.L., Woods J. Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci 2011, 12:124.
97. Whitaker J.W., et al. An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype. Genome Med 2013, 5(4):40.
98. Mathews H.L., et al. Epigenetic patterns associated with the immune dysregulation that accompanies psychosocial distress. Brain Behav Immun 2011, 25(5):830-839.
99. Toyokawa S., et al. How does the social environment 'get into the mind'? Epigenetics at the intersection of social and psychiatric epidemiology. Soc Sci Med 2012, 74(1):67-74.
100. Ai S., et al. DNA methylation as a biomarker for neuropsychiatric diseases. Int J Neurosci 2012, 122(4):165-176.
101. Monk J.P., et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006, 24(12):1852-1859.
102. Raison C.L., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70(1):31-41.
103. Iwata M., Ota K.T., Duman R.S. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 2013, 31:105-114.
104. Perez-Medrano A., et al. Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain. J Med Chem 2009, 52(10):3366-3376.
105. Shiue H.S., et al. DNA microarray analysis of the effect on inflammation in patients treated with acupuncture for allergic rhinitis. J Altern Complement Med 2008, 14(6):689-698.
106. Zhang Z.J., Wang X.M., McAlonan G.M. Neural acupuncture unit: a new concept for interpreting effects and mechanisms of acupuncture. Evid Based Complement Alternat Med 2012, 2012:429412.
107. Garcia M.K., et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013, 31(7):952-960.
108. Chou P., Chu H., Lin J.G. Effects of electroacupuncture treatment on impaired cognition and quality of life in Taiwanese stroke patients. J Altern Complement Med 2009, 15(10):1067-1073.
109. Deng Q.S., Fang Z.C., Yin Y. Ionic mechanism of acupuncture on improvement of learning and memory in aged mammals. Am J Chin Med 1995, 23(1):1-9.
110. Feng Y., et al. FMRI connectivity analysis of acupuncture effects on the whole brain network in mild cognitive impairment patients. Magn Reson Imaging 2012, 30(5):672-682.
111. Zhao L., et al. Electroacupuncture on the head points for improving gnosia in patients with vascular dementia. J Tradit Chin Med 2009, 29(1):29-34.
112. Wang Z., et al. Effect of acupuncture in mild cognitive impairment and Alzheimer disease: a functional MRI study. PLoS One 2012, 7(8):e42730.
113. Nagahara A.H., Tuszynski M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011, 10(3):209-219.
114. Zeng Y., et al. Epigenetic enhancement of BDNF signaling rescues synaptic plasticity in aging. J Neurosci 2011, 31(49):17800-17810.
115. Egan M.F., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112(2):257-269.
116. Dempster E., et al. Association between BDNF val66 met genotype and episodic memory. Am J Med Genet B Neuropsychiatr Genet 2005, 134B(1):73-75.
117. Hariri A.R., et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003, 23(17):6690-6694.
118. Erickson K.I., et al. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci 2010, 30(15):5368-5375.
119. Zhang X.Y., et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet 2012, 131(7):1187-1195.
120. Connor B., et al. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 1997, 49(1-2):71-81.
121. Narisawa-Saito M., et al. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 1996, 7(18):2925-2928.
122. Hock C.H., et al. Alterations in neurotrophins and neurotrophin receptors in Alzheimer's disease. J Neural Transm Suppl 2000, 59:171-174.
123. Wang W.H., et al. Relationship between brain-derived neurotrophic factor and cognitive function of obstructive sleep apnea/hypopnea syndrome patients. Asian Pac J Trop Med 2012, 5(11):906-910.
124. Kim M.W., et al. Electroacupuncture enhances motor recovery performance with brain-derived neurotrophic factor expression in rats with cerebral infarction. Acupunct Med 2012, 30(3):222-226.
125. Lin X.M., et al. Effect of electroacupuncture on the permeability of blood-brain barrier for nerve growth factor and its relevance to PKC pathway in cerebral ischemia rats. Zhen Ci Yan Jiu 2009, 34(2):110-113.
126. Feinberg A.P. Epigenetics at the epicenter of modern medicine. JAMA 2008, 299(11):1345-1350.
127. Oliveira A.M., Hemstedt T.J., Bading H. Rescue of aging-associated decline in Dnmt3a2 expression restores cognitive abilities. Nat Neurosci 2012, 15(8):1111-1113.
128. Levkovitz Y., et al. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord 2012, 136(3):1174-1178.
129. Miwa M., et al. Effects of betaine on lipopolysaccharide-induced memory impairment in mice and the involvement of GABA transporter 2. J Neuroinflammation 2011, 8:153.
130. Graff J., et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483(7388):222-226.
131. Fass D.M., et al. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology 2013, 64:81-96.
132. Kilgore M., et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35(4):870-880.
133. Huber K., Superti-Furga G. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg Med Chem 2011, 19(12):3616-3624.